てんかん（癲癇）：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Market Outlook 10
3.1 Global Markets 10
3.1.1 Forecast 10
3.1.2 Drivers and Barriers – Global Issues 13
4 Current and Future Players 15
4.1 Overview 15
4.2 Trends in Corporate Strategy 18
4.3 Company Profiles 19
4.3.1 UCB 19
4.3.2 Eisai 21
4.3.3 Pfizer 22
4.3.4 GlaxoSmithKline 24
4.3.5 Novartis 25
4.3.6 Abbott 27
4.3.7 Dainippon Sumitomo Pharma 29
5 Appendix 31
5.1 Bibliography 31
5.2 Abbreviations 32
5.3 Methodology 33
5.4 Forecasting Methodology 33
5.4.1 Prevalent Epilepsy Patients 33
5.4.2 Percent Drug-Treated Patients 34
5.4.3 Drugs Included in Each Therapeutic Class Based on MOA 34
5.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates 35
5.4.5 General Pricing Assumptions 37
5.4.6 Individual Drug Assumptions 38
5.4.7 Generic Erosion 53
5.4.8 Pricing of Pipeline Agents 53
5.5 Physicians and Specialists Included in this Study 54
5.6 Primary Research – Prescriber Survey 55
5.7 About the Authors 56
5.7.1 Authors 56
5.7.2 Global Head of Healthcare 57
5.8 About GlobalData 58
5.9 Contact Us 58
5.10 Disclaimer 58